2-bromo-6-(tert-butyl)pyrazine | 1142195-62-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-bromo-6-(tert-butyl)pyrazine
• 英文别名: 2-Bromo-6-tert-butyl-pyrazine；2-bromo-6-tert-butylpyrazine
• CAS: 1142195-62-7
• 化学式: C₈H₁₁BrN₂
• 分子量: 215.093
• InChiKey: DFZHRKNQRIZZSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-6-(tert-butyl)pyrazine 生成 (7-(6-(tert-Butyl)pyrazin-2-yl)-2-azaspiro[3.5]nonan-2-yl)((1s,3s)-3-hydroxy-3-methylcyclobutyl)methanone
  参考文献：
  名称：

  CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS

  摘要：

  式(I)的化合物及其药用盐、同位素、N-氧化物、溶剂合物和立体异构体，包含它们的药物组合物，制备它们的方法以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、疾病和症状的方法，如与疼痛、精神障碍、神经障碍（包括但不限于抑郁症、重度抑郁症、治疗抵抗性抑郁症、焦虑性抑郁症、自闭症谱系障碍、阿斯伯格综合征和躁狂症）、癌症和眼部疾病相关的疾病状态、疾病和症状：其中R1、R3和L如本文所定义。

  公开号：

  US20220089538A1

文献信息

• Phosphonate compounds for treatment of medical disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US10000516B2

  公开（公告）日：2018-06-19

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

  提供了包含式 I 或其药学上可接受的盐或组合物（其中 A 基上的 R12 或 R13 是膦酸盐取代基 (R32)）的补体因子 D 抑制剂的化合物、使用方法和制造工艺。本文所述的抑制剂以因子 D 为靶点，抑制或调节补体级联。本文所述的因子 D 抑制剂可减少补体的过度活化。
• Amide Compounds for Treatment of Medical Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20170057950A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an amide substituent (R 32 ) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein are capable of reducing the excessive activation of complement.
• Ether Compounds for Treatment of Medical Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20170057993A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an ether substituent (R 32 ) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.
• Phosphonate Compounds for Treatment of Medical Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20170057983A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is a phosphonate substituent (R 32 ) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.
• AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20180177761A1

  公开（公告）日：2018-06-28

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an amino substituent (R 32 ) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.